ABB’s new reaction monitor provides fast and flexible device for laboratories and pilot plants.
ABB has launched a dedicated in-situ monitor for research laboratories and pilot plants in the chemical, petrochemical, pharmaceutical and biopharmaceutical industries.
The MB-Rx reaction monitor features a rugged Hastelloy ATR probe and an intuitive software interface, offering a fast and flexible solution for setting up a wide variety of experiment templates.
The MB-Rx provides a powerful tool for operators looking to obtain a real-time insight into chemical reaction dynamics. The MB-Rx enables key parameters such as kinetics over different phases, reagent consumption and the synthesis of products and by-products to be assessed in real time.
Compact and easy to install, the MB-Rx can be fitted inside crowded fumehoods, providing convenient access to reactors. A major benefit of the MB-Rx is its virtually maintenance-free design. Permanently aligned optics and a light source with an average lifespan of 10 years mean that the MB-Rx requires little servicing throughout its operational life, providing extended uptime and reducing the cost of ownership.
Further savings can also be achieved through the elimination of any consumables. The MB-Rx uses no hygroscopic optics or a cryogenic detector, ruling out the need for optical purging, desiccant cartridges, liquid nitrogen or Stirling coolers.
The MB-Rx reaction monitor is just part of ABB’s wider offering of process, emissions & laboratory analyzer products and systems for real-time analysis of the chemical composition and/or physical properties of a process sample or stream. Other products in the portfolio include FT-IR/FT-NIR spectrometer, turnkey analytical solutions for the petroleum, chemical, life sciences, semiconductor, academic, metallurgy and OEM industries; and spectroradiometers for the remote sensing and aerospace markets.
For more information about the MB-Rx reaction monitor or ABB’s process analyser portfolio, email email@example.com or call 0870 600 6122 ref. ‘MB-Rx’.